炎性介质拮抗剂和药物联合防治增殖性玻璃体视网膜病变

Proliferative vitreoretinopathy (PVR) is a leading cause for loss of vision in which the retinal pigment epithelial (RPE) cells proliferate and result in traction retinal detachment. Inhibition of intraocular cellular proliferation can therefore be of help to prevent and treat PVR. We have shown that inflammatory cytokines play key roles in the development of PVR. In our series of experiments using human cultured RPE cells, human intraocular proliferating membranes and animal models, we observed effects and mechanism of anti-cytokines or inhibition in gene level to the cell proliferation, including interleukine 1 receptor antigonist (IL-1ra), interleukine 6 antisense oligonucleotide, (IL-6-ASON), dexamethasone or daunorubicin, and hypercin, a protein kinase C (PKC) specific inhibitor. Those agents or drugs all showed inhibition of expression of related molecules and cellular proliferation of RPE cells, and reduction of development of PVR in the model. 18 papers, and 4 M.D. and 5 M.S.yield from those research work.

我们已证实炎性细胞因子在增殖性玻璃体视网膜病变发生中起关键作用。拟利用人的细胞培养、人眼内增生膜和动物模型眼，观察炎性介质拮抗剂或基因水平的抑制物对细胞增生的作用，及类固醇和抗代谢药对相关分子表达的影响，从分子和基因水平了解作用机制，评价联合疗法的防治效果，为临床防治该致盲性眼病提供依据。